These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 29126252)

  • 1. Monoamines in glioblastoma: complex biology with therapeutic potential.
    Caragher SP; Hall RR; Ahsan R; Ahmed AU
    Neuro Oncol; 2018 Jul; 20(8):1014-1025. PubMed ID: 29126252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 as a Therapeutic Target for Glioblastoma.
    Liu Y; Li C; Lin J
    Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma.
    Caragher SP; Shireman JM; Huang M; Miska J; Atashi F; Baisiwala S; Hong Park C; Saathoff MR; Warnke L; Xiao T; Lesniak MS; James CD; Meltzer H; Tryba AK; Ahmed AU
    J Neurosci; 2019 Mar; 39(11):1982-1993. PubMed ID: 30651332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapeutic targets and agents for glioblastoma migrating cells.
    Di C; Mattox AK; Harward S; Adamson C
    Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating glioblastoma complexity: the interplay of neurotransmitters and chromatin.
    Romero-Reyes J; Vázquez-Martínez ER; Silva CC; Molina-Hernández A; Díaz NF; Camacho-Arroyo I
    Mol Biol Rep; 2024 Aug; 51(1):912. PubMed ID: 39153092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Development of Glioblastoma Therapeutic Agents.
    Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
    Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of neurotransmitters in glioblastoma multiforme-associated seizures.
    Joghataei MT; Bakhtiarzadeh F; Dehghan S; Ketabforoush AHME; Golab F; Zarbakhsh S; Ahmadirad N
    Int J Dev Neurosci; 2023 Dec; 83(8):677-690. PubMed ID: 37563091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
    Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
    Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT/GSK3β Signaling in Glioblastoma.
    Majewska E; Szeliga M
    Neurochem Res; 2017 Mar; 42(3):918-924. PubMed ID: 27568206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathway analysis of glutamate-mediated, calcium-related signaling in glioma progression.
    Pei Z; Lee KC; Khan A; Erisnor G; Wang HY
    Biochem Pharmacol; 2020 Jun; 176():113814. PubMed ID: 31954716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
    Nana AW; Yang PM; Lin HY
    Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
    Garrido W; Rocha JD; Jaramillo C; Fernandez K; Oyarzun C; San Martin R; Quezada C
    Curr Drug Targets; 2014; 15(10):931-42. PubMed ID: 25174341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.
    Gray GK; McFarland BC; Nozell SE; Benveniste EN
    Expert Rev Neurother; 2014 Nov; 14(11):1293-306. PubMed ID: 25262780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence.
    Mecca C; Giambanco I; Donato R; Arcuri C
    Dis Markers; 2018; 2018():9230479. PubMed ID: 30662577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
    Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
    Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.